Motilal Oswal recommended Neutral rating on Aurobindo Pharma with a target price of Rs 600 in its research report dated May 29, 2023.

Buy Aurobindo Pharma; target of Rs 660: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 660 in its research report dated May 29, 2023.

Neutral Aurobindo Pharma; target of Rs 500: Motilal Oswal

Motilal Oswal recommended Neutral rating on Aurobindo Pharma with a target price of Rs 500 in its research report dated February 10, 2023.

Hold Aurobindo Pharma; target of Rs 516: Sharekhan

Sharekhan recommended hold rating on Aurobindo Pharma with a target price of Rs 516 in its research report dated February 10, 2023.

Buy Aurobindo Pharma; target of Rs 554: Geojit

Geojit is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 554 in its research report dated March 02, 2023.

Buy Aurobindo Pharma; target of Rs 565: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 565 in its research report dated February 11, 2023.

Accumulate Aurobindo Pharma; target of Rs 550: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Aurobindo Pharma with a target price of Rs 550 in its research report dated November 16, 2022.

Neutral Aurobindo Pharma; target of Rs 500: Motilal Oswal

Motilal Oswal recommended Neutral rating on Aurobindo Pharma with a target price of Rs 500 in its research report dated November 14, 2022.

Hold Aurobindo Pharma; target of Rs 540: ICICI Direct

ICICI Direct recommended hold rating on Aurobindo Pharma with a target price of Rs 540 in its research report dated November 14, 2022.

Accumulate Aurobindo Pharma; target of Rs 626: KR Choksey

KR Choksey recommended accumulate rating on Aurobindo Pharma with a target price of Rs 626 in its research report dated August 18, 2022.

Accumulate Aurobindo Pharma; target of Rs 635: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Aurobindo Pharma with a target price of Rs 635 in its research report dated August 15, 2022.

Hold Aurobindo Pharma; target of Rs 640: Sharekhan

Sharekhan recommended hold rating on Aurobindo Pharma with a target price of Rs 640 in its research report dated August 12, 2022.

Hold Aurobindo Pharma; target of Rs 615: ICICI Direct

ICICI Direct recommended hold rating on Aurobindo Pharma with a target price of Rs 615 in its research report dated August 12, 2022.

Buy Aurobindo Pharma; target of Rs 875: Sharekhan

Sharekhan is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 875 in its research report dated February 10, 2022.

Accumulate Aurobindo Pharma; target of Rs 759: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Aurobindo Pharma with a target price of Rs 759 in its research report February 10, 2022.

Accumulate Aurobindo Pharma; target of Rs 756: KR Choksey

KR Choksey recommended accumulate rating on Aurobindo Pharma with a target price of Rs 756 in its research report dated February 11, 2022.

Will the Street reward Aurobindo Pharma’s bet on domestic formulations?

The Aurobindo Pharma stock currently trades at a valuation of 6.6x FY23e EV/EBITDA, which is at a substantial discount to its Indian peers with an exposure in the US market

Buy Aurobindo Pharma; target of Rs 915: Sharekhan

Sharekhan is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 915 in its research report dated August 13, 2021.

Aurobindo Pharma: Termination of inorganic bet eases capital allocation worries

We believe termination of the Cronus Pharma acquisition deal should help remove corporate governance/capital allocation fears

Aurobindo Pharma: Value proposition intact, but consolidation can take longer

In this injectables space, Aurobindo pharma remains constructive and plans to grow from the current annual sales base of $400 million to 650-700 million in three years, backed by new plants in the US and Vizag.

Dr Reddy’s: Growth story remains intact; margins key monitorable

Dr Reddy's margins are likely to be weighed by recurring investments - digitization, brand building exercise & elevated R&D - in near to medium term

Accumulate Aurobindo Pharma; target of Rs 1044: KR Choksey

KR Choksey recommended accumulate rating on Aurobindo Pharma with a target price of Rs 1044 in its research report dated Jun 03, 2021.

Buy Aurobindo Pharma target of Rs 1139: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1139 in its research report dated Jun 01, 2021.

Buy Aurobindo Pharma; target of Rs 1165: ICICI Direct

ICICI Direct is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1165 in its research report dated Jun 01, 2021.

Buy Aurobindo Pharma: target of Rs 1185: Sharekhan

Sharekhan is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1185 in its research report dated May 31, 2021.